publication . Conference object . Article . 2018

Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials

von Waldenfels, Gabriel; Loibl, Sibylle; Furlanetto, Jenny; Machleidt, Anna; Lederer, Bianca; Denkert, Carsten; Hanusch, Claus; Kümmel, Sherko; von Minckwitz, Gunter; Schneeweiss, Andreas; ...
Open Access
  • Published: 20 Sep 2018
  • Publisher: Georg Thieme Verlag KG
Abstract
// Gabriel von Waldenfels 1 , Sibylle Loibl 2 , Jenny Furlanetto 2 , Anna Machleidt 1 , Bianca Lederer 2 , Carsten Denkert 3 , Claus Hanusch 4 , Sherko Kummel 5 , Gunter von Minckwitz 2 , Andreas Schneeweiss 6 , Michael Untch 7 , Kerstin Rhiem 8 , Peter A. Fasching 9 and Jens-Uwe Blohmer 1 1 Department of Gynecology and Breast Center, Charite University Hospital, Berlin, Germany 2 German Breast Group, Neu-Isenburg, Germany 3 Institute of Pathology, Charite University Hospital, Berlin, Germany 4 Rotkreuzklinikum, Munich, Germany 5 Breast Center, Kliniken Essen-Mitte, Essen, Germany 6 National Center for Tumor Diseases (NCT), Heidelberg, Germany 7 HELIOS Klinikum ...
Subjects
free text keywords: Oncology, medicine.medical_specialty, medicine, Randomized controlled trial, law.invention, law, Chemotherapy, medicine.medical_treatment, Breast cancer, medicine.disease, Internal medicine, business.industry, business, Ovarian cancer, Multivariate analysis, Logistic regression, Lymph node, medicine.anatomical_structure, Cancer, Anthracycline, Immunology, Research Paper: Gerotarget (Focus on Aging), elderly, pCR, neoadjuvant, breast, cancer survival, Gerotarget
30 references, page 1 of 2

Biganzoli, L, Wildiers, H, Oakman, C, Marotti, L, Loibl, S, Kunkler, I, Reed, M, Ciatto, S, Voogd, AC, Brain, E, Cutuli, B, Terret, C, Gosney, M. Management of elderly patients with breast cancer: Updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012; 13: e148-60 [OpenAIRE] [PubMed]

Barinoff, J, Traut, A, Bauerschlag, D, Bischoff, J, Herr, D, Lübbe, K, Lück, HJ, Maass, N, Mundhenke, C, Schmidt, M, Schwedler, K, Thill, M, Steffen, J. Chemotherapy for 70-Year-old women with breast cancer in Germany: A survey by the German breast group. Geburtshilfe Frauenheilkd. 2013; 73: 433-9 [OpenAIRE] [PubMed]

Hutchins, LF, Unger, JM, Crowley, JJ, Coltman, CA, Albain, KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 2061-7 [OpenAIRE] [PubMed]

Kumar, A, Soares, HP, Balducci, L, Djulbegovic, B. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol. 2007; 25: 1272-76 [PubMed]

Von Minckwitz, G, Untch, M, Blohmer, JU, Costa, SD, Eidtmann, H, Fasching, PA, Gerber, B, Eiermann, W, Hilfrich, J, Huober, J, Jackisch, C, Kaufmann, M, Konecny, GE. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30: 1796-804 [PubMed]

Loibl, S, Jackisch, C, Lederer, B, Untch, M, Paepke, S, Kümmel, S, Schneeweiss, A, Huober, J, Hilfrich, J, Hanusch, C, Gerber, B, Eidtmann, H, Denkert, C. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat. 2015; 152: 377-87 [OpenAIRE] [PubMed]

Loibl, S, von Minckwitz, G, Untch, M, Denkert, C. Predictive factors for response to neoadjuvant therapy in breast cancer. Oncol Res Treat. 2014; 37: 563-68 [OpenAIRE] [PubMed]

Halfter, K, Ditsch, N, Kolberg, HC, Fischer, H, Hauzenberger, T, von Koch, FE, Bauerfeind, I, von Minckwitz, G, Funke, I, Crispin, A, Mayer, B. Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy—the SpheroNEO study. BMC Cancer. 2015; 15: 519 [OpenAIRE] [PubMed]

von Minckwitz, G, Raab, G, Caputo, A, Schütte, M, Hilfrich, J, Blohmer, JU, Gerber, B, Costa, SD, Merkle, E, Eidtmann, H, Lampe, D, Jackisch, C, du Bois, A, Kaufmann, M. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005; 23: 2676-85 [OpenAIRE] [PubMed]

von Minckwitz, G, Blohmer, JU, Raab, G, Löhr, A, Gerber, B, Heinrich, G, Eidtmann, H, Kaufmann, M, Hilfrich, J, Jackisch, C, Zuna, I, Costa, SD. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol. 2005; 16: 56-63 [PubMed]

von Minckwitz, G, Kümmel, S, Vogel, P, Hanusch, C, Eidtmann, H, Hilfrich, J, Gerber, B, Huober, J, Costa, SD, Jackisch, C, Loibl, S, Mehta, K, Kaufmann, M. Intensified neoadjuvant chemotherapy in early-responding breast cancer: Phase III randomized GeparTrio study. J Natl Cancer Inst. 2008; 100: 552-62 [OpenAIRE] [PubMed]

Untch, M, Rezai, M, Loibl, S, Fasching, PA, Huober, J, Tesch, H, Bauerfeind, I, Hilfrich, J, Eidtmann, H, Gerber, B, Hanusch, C, Küehn, T, Du Bois, A. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study. J Clin Oncol. 2010; 28: 2024-31 [OpenAIRE] [PubMed]

Untch, M, Möebus, V, Kuhn, W, Muck, BR, Thomssen, C, Bauerfeind, I, Harbeck, N, Werner, C, Lebeau, A, Schneeweiss, A, Kahlert, S, Von Koch, F, Petry, KU. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009; 27: 2938-45 [OpenAIRE] [PubMed]

Untch, M, Fasching, PA, Konecny, GE, von Koch, F, Conrad, U, Fett, W, Kurzeder, C, Lück, HJ, Stickeler, E, Urbaczyk, H, Liedtke, B, Salat, C, Harbeck, N. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery. Ann Oncol. 2011; 22: 1988-98 [OpenAIRE] [PubMed]

Untch, M, Fasching, PA, Konecny, GE, Hasmüller, S, Lebeau, A, Kreienberg, R, Camara, O, Müller, V, du Bois, A, Kühn, T. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2–overexpressing breast cancer: Results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. American Society of Clinical Oncology. 2011; 29: 3351-7 [OpenAIRE]

30 references, page 1 of 2
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Conference object . Article . 2018

Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials

von Waldenfels, Gabriel; Loibl, Sibylle; Furlanetto, Jenny; Machleidt, Anna; Lederer, Bianca; Denkert, Carsten; Hanusch, Claus; Kümmel, Sherko; von Minckwitz, Gunter; Schneeweiss, Andreas; ...